Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.10

-4.5%

10:27 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	9/19/2000 8:01:32 AM
From: IRWIN JAMES FRANKEL	Read Replies (2) of 52153

ITMN Yesterday the company issued a press release: Message 14401347 It looks to me like this study is targeting treatment of Pseudomonas aeruginosa which is very common in cystic fibrosis. It would fit with ITMN's focus of using gamma interferon 1b in fibrotic lung diseases. Broadening the drug from IPF to CF suggests higher valuations are coming for ITMN. Does my read on where they are going make sense? ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next